Goździk Jolanta, Czajka Hanna, Paradowska-Stankiewicz Iwona, Skoczeń Szymon, Czogała Wojciech, Krasowska-Kwiecień Aleksandra, Wiecha Oktawiusz
Department of Clinical Immunology and Transplantatology, Polish-American Institute of Paediatrics, Jagiellonian University Medical College, Cracow.
Przegl Epidemiol. 2012;66(1):93-8.
patients treated with hematopoietic stem cell transplantation (HSCT) lose immune memory accumulated through a lifetime. They are at increased risk of developing infections with microorganisms such as Haemophilus influenza, Streptococcus pneumoniae and others for which vaccines are available. Therefore, all patients after HSCT should be routinely revaccinated. Systemic reimmunization after HSCT is a relatively neglected area especially in countries which have not national recommendations and there is lack of systemic regulations in health care system.
the rate of immunization before transplantation and the persistence of vaccine-specific antibodies after HSCT was assessed.
a group of38 children after stem cell transplantation (19 autologous, 19 allogeneic) was studied.
only a few patients completed standard vaccination protocol before HSCT. At the median time of 29 (range: 6-67) months after autologous and 13 (range: 8-33) months after allogeneic HSCT, when the revaccination was commenced, the majority of children had concentration of antibody lower than the minimum protective thresholds. That was 82% for tetanus, 71% for Hib and varicella, 46% for HBV and 38% for diphtheria.
all HSCT recipients should be routinely revaccinated to stimulate the immunity to the vaccine-preventable diseases.
接受造血干细胞移植(HSCT)的患者会失去一生积累的免疫记忆。他们感染流感嗜血杆菌、肺炎链球菌等可通过疫苗预防的微生物的风险增加。因此,所有HSCT后的患者都应常规重新接种疫苗。HSCT后的全身再免疫是一个相对被忽视的领域,尤其是在没有国家建议且医疗保健系统缺乏系统性规定的国家。
评估移植前的免疫接种率以及HSCT后疫苗特异性抗体的持久性。
对一组38名干细胞移植后的儿童(19名自体移植,19名异体移植)进行了研究。
只有少数患者在HSCT前完成了标准疫苗接种方案。在自体HSCT后29个月(范围:6 - 67个月)和异体HSCT后13个月(范围:8 - 33个月)的中位时间开始重新接种疫苗时,大多数儿童的抗体浓度低于最低保护阈值。破伤风为82%,b型流感嗜血杆菌结合疫苗(Hib)和水痘为71%,乙肝病毒(HBV)为46%,白喉为38%。
所有HSCT受者都应常规重新接种疫苗,以刺激对疫苗可预防疾病的免疫力。